Brief: Oncoarendi Therapeutics H1 Net Loss Widens To 2.0 Mln Zlotys
24/09/2019 17:36
Sept 24 (Reuters) - Oncoarendi Therapeutics SA OAT.WA :
* H1 OPERATING REVENUE 0.9 MILLION ZLOTYS VERSUS 0.6 MILLION
ZLOTYS YEAR AGO
* H1 NET LOSS 2.0 MILLION ZLOTYS VERSUS LOSS OF 1.9 MILLION
ZLOTYS
YEAR AGO
Source text for Eikon: ID:nEM1cfNWVa
Further company coverage: OAT.WA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Molecure SA
See all newsBrief: Molecure Q1 Net Loss 4.1 Mln Zlotys
Brief: Molecure Says Its In-Consortium Project Selected For Funding By Medical Research Agency
Brief: Molecure To Sell 4.12 Mln Series K Shares and 2.0 Mln Existing Shares At 5 Zlotys/Shr
Brief: Molecure Starts ABB For Up to 4.12 Mln New Series K Shares And Up To 2.0 Mln Existing Shares
Brief: Molecure Signs Conditional Investment Agreement With MS Galleon And Szumowski Investments